Leonard J. Cerullo, M.D.

Leonard J. Cerullo, M.D.

Leonard J. Cerullo, M.D.

Log into NorthShoreConnect


Personal Bio

Treatment Philosophy

I believe in treating the whole person, not just the disease. I think it is important to utilize the highest technology combined with the best communication, with the patient, the family, and the other treating physicians. Being available to the patient at all times and encouraging open and honest communication is essential. I believe that healing requires the spirit, as well as the body. If the patient is not part of the healing process, he becomes part of the disease.

Personal Interests

My outside interests include enjoying literature, languages and all types of food.

Conditions & Procedures


Acoustic Neuroma, Arnold-Chiari Malformation, astrocytoma, Brain Bleed, Brain Cancer, Brain Tumor, Cranial Base Tumors, Ependynoma, Glioblastoma, Glioma, Meningioma, Neoplasm, Pineal Cyst, Skull Base Tumors, Subarachnoid Hemorrhage (SAH), Subdural Hematoma (SDH), Syringomyelia, Vestibular Schwanoma


Acoustic Neuroma Surgery, Brain Surgery, Skull Base Surgery, Trigeminal Neuralgia Surgery

General Information




NorthShore Medical Group


English, Italian

Board Certified

Neurological Surgery

Clinical Service

Education, Training & Fellowships

Medical School

Jefferson Medical College, 1970


Chicago Wesley Memorial, 1971


Lankenau Hospital, 1972
Northwestern Feinberg School of Medicine, 1977


Hospital Foch, 1974
Columbia University Neurological Institute, 1975



NOI NorthShore Orthopedics Chicago

680 N Lake Shore Dr
Ste 924
Chicago, IL 60611
847.570.1440 847.570.1442 fax Get Directions This location is wheelchair accessible.

NorthShore Medical Group

225 N. Milwaukee Ave.
Suite 1500
Vernon Hills, IL 60061
847.570.1440 847.570.1442 fax Get Directions This location is wheelchair accessible.

NorthShore Medical Group

9650 Gross Point Rd.
Suite 3900
Skokie, IL 60076
847.570.1440 847.570.1442 fax Get Directions This location is wheelchair accessible.


Commercial Plans
  • Aetna Choice POS
  • Aetna Elect Choice EPO and EPO
  • Aetna Health Network Options
  • Aetna HMO
  • Aetna Managed Choice
  • Aetna Managed Choice POS
  • Aetna Open Choice PPO
  • Aetna Open Choice PPO (Aetna HealthFund)
  • Aetna QPOS
  • Aetna Savings Plus
  • Aetna Select
  • Beechstreet PPO Network
  • Blue Cross Blue Shield - PPO Products
    Not Contracted Blue Cross Blue Shield Blue Choice PPO
  • Blue Cross Blue Shield Blue Advantage
  • Blue Cross Blue Shield HMOI
  • Cigna HMO
  • Cigna LocalPlus
  • Cigna Open Access Plus (OAP)
  • Cigna Open Access Plus with CareLink (OAPC)
  • Cigna POS
  • Cigna PPO
  • Cofinity PPO (an Aetna Company)
  • Coventry Health Care Elect Choice EPO
  • Coventry Health Care First Health PPO
  • Galaxy Health PPO Network
  • Great West PPO/POS
  • Healthcare's Finest Network (HFN)
  • Humana - All Commercial Plans (including Choice Care)
  • Humana - NorthShore Complete Care
  • Humana/ChoiceCare Network PPO
  • Medicare
  • Multiplan and PHCS PPO Network (Including PHCS Savility)
  • NorthShore Employee Network
  • Preferred Plan PPO
  • Three Rivers Provider PPO Network (TRPN)
  • Tricare
  • Unicare
  • United Healthcare - All Commercial Plans
    Not Contracted United Healthcare Core
    Not Contracted United Healthcare Navigate
Exchange Plans
  • Aetna Whole Health Chicago
  • Not Contracted Blue Cross Blue Shield - PPO Products
    Not Contracted Blue Cross Blue Shield Blue Choice PPO
  • Blue Cross Blue Shield Blue Precision HMO
  • Coventry (PPO)
  • Harken Health - an Affiliate of United Healthcare
    Verify physician participation and out of pocket expenses with Harken
  • Land of Lincoln Health Traditional PPO
  • Not Contracted United Healthcare Compass
  • Illinois Department of Public Aid (IDPA)
  • Illinicare ICP
  • Community Care Partners
Medicare Advantage Plans
  • Aetna Medicare (SM) Plan (HMO)
  • Aetna Medicare (SM) Plan (PPO)
  • Blue Cross Blue Shield Medicare Advantage PPO Plan
  • Cigna-HealthSpring Advantage HMO
  • Cigna-HealthSpring Premier HMO-POS
  • Cigna-HealthSpring Primary HMO
  • Humana Gold Plus HMO
  • Humana Gold Plus PFFS
  • HumanaChoice PPO
  • United Healthcare - All Medicare Plans
Medicare Medicaid Alignment Initiative (MMAI) Plans
  • Blue Cross Blue Shield Community
  • HealthSpring
  • Humana
  • Illinicare Health Plan
  • Meridian Complete


  • Genomic expression discovery predicts pathways and opposing functions behind phenotypes.

    The Journal of biological chemistry 2003 Jun 27

    Authors: Fathallah-Shaykh HM, He B, Zhao LJ, Engelhard HH, Cerullo L, Lichtor T, Byrne R, Munoz L, Von Roenn K, Rosseau GL, Glick R, Sherman C, Farooq K
    Discovering states of genetic expression that are true to a high degree of certainty is likely to predict gene function behind biological phenotypes. The states of expression (up- or down-regulated) of 19200 cDNAs in 10 meningiomas are compared with normal brain by an algorithm that detects only 1 false measurement per 192000; 364 genes are discovered. The expression data accurately predict activation of signaling pathways and link gene function to specific phenotypes. Meningiomas appear to acquire aberrant phenotypes by disturbing the balanced expression of molecules that promote opposing functions. The findings expose interconnected genes and propose a role of genomic expression discovery in functional genomics of living systems.
    PMID: 12700229 [PubMed - as supplied by publisher]
  • Mathematical modeling of noise and discovery of genetic expression classes in gliomas.

    Oncogene 2002 Oct 17

    Authors: Fathallah-Shaykh HM, Rigen M, Zhao LJ, Bansal K, He B, Engelhard HH, Cerullo L, Roenn KV, Byrne R, Munoz L, Rosseau GL, Glick R, Lichtor T, DiSavino E
    The microarray array experimental system generates noisy data that require validation by other experimental methods for measuring gene expression. Here we present an algebraic modeling of noise that extracts expression measurements true to a high degree of confidence. This work profiles the expression of 19 200 cDNAs in 35 human gliomas; the experiments are designed to generate four replicate spots/gene with switching of probes. The validity of the extracted measurements is confirmed by: (1) cluster analysis that generates a molecular classification differentiating glioblastoma from lower-grade tumors and radiation necrosis; (2) By what other investigators have reported in gliomas using paradigms for assaying molecular expression other than gene profiling; and (3) Real-time RT-PCR. The results yield a genetic analysis of gliomas and identify classes of genetic expression that link novel genes to the biology of gliomas.
    PMID: 12370806 [PubMed - as supplied by publisher]
  • The identification of novel therapeutic targets for the treatment of malignant brain tumors.

    Cancer letters 2000 Aug 11

    Authors: Kroes RA, Jastrow A, McLone MG, Yamamoto H, Colley P, Kersey DS, Yong VW, Mkrdichian E, Cerullo L, Leestma J, Moskal JR
    A two-step strategy was developed consisting of differential display reverse transcriptase polymerase chain reaction (DDRT-PCR) with cultured normal human fetal astrocytes and U-373MG glioma cells followed by reverse Northern analysis of normal brain and primary tumor tissues. hu-dek, alpha-NAC, ribosomal proteins L7a and L35a, and five novel genes were identified. Since none of these genes has been previously shown to be associated with malignant brain tumor formation, this approach may be useful to identify novel targets for the diagnosis and treatment of brain tumors.
    PMID: 10880769 [PubMed - as supplied by publisher]
  • Beta1,6-N-acetylglucosamine-bearing N-glycans in human gliomas: implications for a role in regulating invasivity.

    Cancer research 2000 Jan 1

    Authors: Yamamoto H, Swoger J, Greene S, Saito T, Hurh J, Sweeley C, Leestma J, Mkrdichian E, Cerullo L, Nishikawa A, Ihara Y, Taniguchi N, Moskal JR
    The metastatic potential of tumor cells has been shown to be correlated with the expression of tri- and tetra-antennary beta1,6-N-acetylglucosamine (beta1,6-GlcNAc)-bearing N-glycans, which are recognized by Phaseolus vulgaris leukoagglutinating lectin (L-PHA). The expression of beta1,6-GlcNAc-bearing N-glycans also has been used as a marker of tumor progression in human breast and colon cancers. In this report, the role of N-glycan branching in regulating glioma migration and invasion was examined. The expression of beta1,6-GlcNAc-bearing N-glycans was found in human glioma specimens, whereas astrocytes from normal adult brain were negative. The expression of N-acetylglucosaminyltransferase V (GnT-V) mRNA, which is responsible for the biosynthesis of beta1,6-GlcNAc-bearing N-glycans, was high in glioma cell lines with robust ets-1 expression. To study the molecular mechanism of GnT-V expression in human glioma cells, an inducible ets-1 gene was stably transfected into SNB-19 cells using a tetracycline repressor system. GnT-V mRNA expression was increased by the induction of c-ets-1, suggesting that the Ets-1 transcription factor directly regulates the transcription of GnT-V. Stable transfection of GnT-V into human glioma U-373 MG cells resulted in changes in cell morphology and focal adhesions and a marked increase in glioma invasivity in vitro. L-PHA has little effect on cell migration. On the contrary, Phaseolus vulgaris erythroagglutinating lectin (E-PHA), which recognizes bisecting beta1,4-GlcNAc-bearing N-glycans, strongly inhibits cell migration (haptotaxis) on a fibronectin substrate in U-373 MG transfectants and other glioma cell lines tested. These results suggest that the increased beta1,6-GlcNAc-bearing N-glycan expression found in malignant gliomas is modulated by GnT-V through the Ets-1 transcription factor, and that the branching of complex type N-glycans plays a major role in glioma invasivity.
    PMID: 10646865 [PubMed - as supplied by publisher]
  • Recurrence of vestibular (acoustic) schwannomas in surgical patients where preservation of facial and cochlear nerve is the priority.

    British journal of neurosurgery 1998 Dec

    Authors: Cerullo L, Grutsch J, Osterdock R
    The risk of tumour recurrence was measured in a series of surgically treated vestibular (acoustic) schwannoma patients where preservation of facial and cochlear nerve function was a routine objective. This report describes the influence of this surgical philosophy on the hazards of tumour recurrence or continued growth from residual tumour cells left in situ. A series of 116 consecutive vestibular schwannoma patients underwent primary surgical resection in a general community hospital by a single neurosurgeon. Recurrence of a tumour was assessed radiologically. Eighteen patients experienced a recurrence. No relationship was found between recurrence and age, residual coagulated morsels of tumour, preoperative tumour size, or opening of the internal auditory canal. Time to recurrence ranged from six to one hundred and forty-eight months and all but two recurrent lesions were non symptomatic. Lifelong follow-up of these patients is therefore, suggested.
    PMID: 10070464 [PubMed - as supplied by publisher]
  • alpha2,3-sialyltransferase mRNA and alpha2,3-linked glycoprotein sialylation are increased in malignant gliomas.

    Brain research 1997 Apr 25

    Authors: Yamamoto H, Saito T, Kaneko Y, Kersey D, Yong VW, Bremer EG, Mkrdichian E, Cerullo L, Leestma J, Moskal JR
    CMP-NeuAc: Galbeta1,3(4)GlcNAc alpha2,3-sialyltransferase (alpha2,3-ST) mRNA was expressed in human glioma specimens, human fetal astrocytes, and a panel of brain tumor cell lines. Maackia amurensis agglutinin staining revealed the presence of alpha2,3-linked sialic acids on glioma cell surfaces and extracellular matrices whereas normal human adult astrocytes were negative. Increased expression of alpha2,3-linked glycoprotein sialylation may play a role in glial tumorigenesis.
    PMID: 9163557 [PubMed - as supplied by publisher]
  • Intracranial chondroma arising from the cranial vault: CT and MR appearance.

    Journal of computer assisted tomography

    Authors: Abdelhamid K, Camras LR, Nijensohn EM, Rosseau GL, Cerullo LJ
    A case of intracranial chondroma arising from the right parietal bone in a 37-year-old woman is presented. CT and MRI findings as well as the differential diagnosis of the lesion are discussed.
    PMID: 8708055 [PubMed - as supplied by publisher]
  • Prospective surveillance for perioperative venous thrombosis. Experience in 2643 patients.

    Archives of surgery (Chicago, Ill. : 1960) 1996 May

    Authors: Flinn WR, Sandager GP, Silva MB
    Patients who undergo neurosurgical procedures are at high risk for perioperative deep vein thrombosis (DVT) and pulmonary embolism (PE), which have been reported in 6% to 43% of these patients.
    To (1) determine the utility of prospective DVT surveillance in patients who undergo neurosurgical procedures by using venous duplex ultrasound scanning (VDUS), (2) assess the efficacy of DVT prophylaxis (elastic stockings and intermittent pneumatic compression), (3) identify subgroups of patients who are at higher risk, and (4) determine whether DVT surveillance would reduce the incidence of fatal PE.
    All patients had undergone preoperative VDUS of both lower extremities, and postoperative VDUS was performed on days 3 and 7, and weekly thereafter until patients were ambulatory or discharged.
    During a 5-year period, 2643 patients who underwent neurosurgical procedures were enrolled in prospective DVT surveillance.
    University-affiliated community hospital.
    Acute DVT was diagnosed in 147 (5.6%) of the 2643 patients. Eighty-one percent of the patients with acute DVT were asymptomatic at the time of diagnosis. Deep vein thrombosis developed de novo in the proximal veins in 98% of the patients. Patients in whom a craniotomy was done had a significantly higher risk for DVT (7.7%, P = .006), and patients who underwent cervical or lumbar spinal surgical procedures had a significantly lower risk (1.5%, P < .001). Among those patients in whom a craniotomy was performed for treatment of a tumor and who had DVT, 87% had malignant neoplasms. Significant lower-extremity neuromotor dysfunction was present in 69% of all patients with DVT, and this finding predominated among patients with DVT in the subgroups with a lower risk. A PE was diagnosed in 5 patients (0.19%) while they were hospitalized, and a PE was fatal in 2 (0.07% of all patients).
    Most perioperative DVTs were clinically silent and formed spontaneously in proximal venous segments where there would be a risk for a PE. The overall incidence of DVT (5.6%) was low, suggesting effective DVT prophylaxis. Patients who underwent spinal surgical procedures were at a significantly lower risk for DVT, and future surveillance is not indicated in this patient group unless other conditions exist (paralysis, malignancy). Patients in whom a craniotomy was performed had a significantly higher risk of DVT, particularly when other risk factors existed. The low incidence of a fatal PE (0.07%) reflected that early detection and treatment of proximal DVT were facilitated by prospective VDUS surveillance in these patients.
    PMID: 8624191 [PubMed - as supplied by publisher]
  • The expression of CMP-NeuAc: Gal beta 1,4GlcNAc alpha 2,6 sialyltransferase [EC] and glycoproteins bearing alpha 2,6-linked sialic acids in human brain tumours.

    Glycoconjugate journal 1995 Dec

    Authors: Yamamoto H, Kaneko Y, Vandermulen D, Kersey D, Mkrdichian E, Cerullo L, Leestma J, Moskal JR
    The expression of CMP-NeuAc: Gal beta 1,4GlcNAc alpha 2,6 sialyltransferase (alpha 2,6-ST) [EC] and glycoproteins bearing alpha 2,6-linked sialic acids were examined in primary human brain tumours and cell lines. 79% (19/24) of the meningiomas expressed alpha 2,6-ST mRNA, 42% (10/24) of which showed very high expression. alpha 2,6-ST mRNA expression was undetectable in normal brain tissue. In contrast, only 1/13 of the gliomas examined expressed detectable alpha 2,6-ST mRNA. Metastases to the brain did not express measurable amounts of alpha 2,6-ST mRNA. Less expression was found in malignant (i.e. anaplastic) compared to benign (i.e. meningothelial) meningiomas. Two-dimensional SDS-PAGE of glioma and meningioma proteins, followed by Sambucus nigra lectin staining, revealed the presence of a glycoprotein bearing alpha 2,6-linked sialic acids, M(r) = 53 kDa and a pI = 7.0 (MEN-1) that appeared in all seven of the meningiomas examined, but was expressed at barely detectable levels, if at all, in seven out of the seven glioblastomas examined. Thus, decreased alpha 2,6-ST expression may play a role in the aggressive nature of anaplastic meningiomas, but appears to be virtually absent in all tumours of glial origin.
    PMID: 8748163 [PubMed - as supplied by publisher]
  • The preservation of hearing and facial nerve function in a consecutive series of unilateral vestibular nerve schwannoma surgical patients (acoustic neuroma).

    Surgical neurology 1993 Jun

    Authors: Cerullo LJ, Grutsch JF, Heiferman K, Osterdock R
    Between January 1981 and February 1992, 102 non-NF-2 patients underwent removal of a unilateral vesitbular schwannoma. There were 54 women and 48 men. Eighty-six percent of patients with normal facial function preoperatively retained normal function (House score 1 or 2) postoperatively. Of the 64 patients with a functional cochlear nerve preoperatively, five had normal hearing (PTA < 25 dB, SB > 70%), five had near normal hearing (PTA < 45 dB, SD > 70%), four patients had preserved hearing (PTA < 50 dB, SD > 50%), and three patients had preserved cochlear nerve function (PTA > 50 dB, SD < 50%) after surgery. Hearing preservation was obtained in patients whose tumors were larger than 3 cm. Radiological follow-up revealed 10 patients with recurrent tumor, all but one asymptomatic.
    PMID: 8516747 [PubMed - as supplied by publisher]